Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-051566
Filing Date
2025-04-07
Accepted
2025-04-07 16:02:12
Documents
92
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K rntx-20241231.htm   iXBRL 10-K 3655786
2 EX-19.1 rntx-ex19_1.htm EX-19.1 74587
3 EX-23.1 rntx-ex23_1.htm EX-23.1 4799
4 EX-31.1 rntx-ex31_1.htm EX-31.1 12166
5 EX-31.2 rntx-ex31_2.htm EX-31.2 13068
6 EX-32.1 rntx-ex32_1.htm EX-32.1 8049
7 EX-32.2 rntx-ex32_2.htm EX-32.2 7984
  Complete submission text file 0000950170-25-051566.txt   12949705

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rntx-20241231.xsd EX-101.SCH 1902719
95 EXTRACTED XBRL INSTANCE DOCUMENT rntx-20241231_htm.xml XML 1888401
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38130 | Film No.: 25818096
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)